4.6 Article

Hybrid Nanoparticles as Drug Carriers for Controlled Chemotherapy of Cancer

Journal

CHEMICAL RECORD
Volume 16, Issue 4, Pages 1833-1851

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/tcr.201600029

Keywords

cancer; controlled release; drug delivery; nanoparticles; stimuli responsiveness

Funding

  1. National Research Foundation (NRF), Prime Minister's Office, Singapore, under its Campus for Research Excellence and Technological Enterprise (CREATE) Programme-Singapore Peking University Research Centre for a Sustainable Low-Carbon Future
  2. NTU-A*Star Silicon Technologies Centre of Excellence [11235100003]
  3. NTU-Northwestern Institute for Nanomedicine
  4. International Postdoctoral Exchange Program
  5. Fundamental Research Funds for the Central Universities

Ask authors/readers for more resources

Rapid developments in materials science and biological mechanisms have greatly boosted the research discoveries of new drug delivery systems. In the past few decades, hundreds of nanoparticle-based drug carriers have been reported almost on a daily basis, in which new materials, structures, and mechanisms are proposed and evaluated. Standing out among the drug carriers, the hybrid nanoparticle systems offer a great opportunity for the optimization and improvement of conventional chemotherapy. By combining several features of functional components, these hybrid nanoparticles have shown excellent promises of improved biosafety, biocompatibility, multifunctionality, biodegradability, and so forth. In this Personal Account, we highlight the recent research advances of some representative hybrid nanoparticles as drug delivery systems and discuss their design strategies and responsive mechanisms for controlled drug delivery.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available